Hexarelin
Growth hormone-releasing hexapeptide
The strongest GH pulse of the GHRPs.
Half-life
~ 1–2 hours
Mol. weight
887.4 g/mol
Sequence
His-D-2-Me-Trp-Ala-Trp-D-Phe-Lys-NH2
Discussions
0 threads
Overview
A synthetic hexapeptide ghrelin-receptor (GHS-R1a) agonist studied for producing one of the most potent GH-releasing signals in the GHRP class. It is more potent than GHRP-6 and GHRP-2, though it shares the class's appetite and cortisol/prolactin considerations and may have additional cardiac effects under investigation.
Mechanism of action
Hexarelin agonizes the ghrelin receptor (GHS-R1a) to stimulate growth hormone release from pituitary somatotrophs, producing a larger GH pulse than the other GHRPs. Beyond the pituitary, it also appears to interact with cardiac receptors (a CD36-linked pathway), which has prompted separate research into potential cardioprotective effects — though this remains preclinical and distinct from its GH-releasing use.
Researched benefits
- Among the most potent GHRPs for GH release
- Studied for body composition and recovery
- Potential cardiac signaling under research
Considerations
- Can increase appetite
- May raise cortisol and prolactin
- Cardiac effects not fully characterized
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Hexarelin in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Hexarelin:
View Hexarelin index on PubMed (NCBI)